Plain-English translation of NCT05275738 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether nicotinamide, a form of vitamin B3, can help slow or prevent vision loss in people with newly diagnosed glaucoma. Participants will take either nicotinamide tablets or a placebo (inactive pill) for two years while researchers track changes in their vision and eye pressure. The goal is to see if this affordable, natural B vitamin might protect eyesight in glaucoma patients.
Glaucoma damages the optic nerve and causes progressive vision loss, and current treatments focus mainly on lowering eye pressure. Researchers want to know if this medication might offer additional protection to the nerve itself, potentially offering patients another way to preserve their sight.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to take either nicotinamide tablets or placebo pills daily for two years. You'll start with a lower dose for 6 weeks, then move to a higher dose for the rest of the study. During your participation, you'll have regular eye exams to measure your eye pressure and vision field, allowing researchers to see if the medication helps protect your sight. Neither you nor the doctors will know whether you're taking the real medication or placebo until the study ends.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Sweden
Sponsor
Umeå University
Collaborators
Center for Eye Research Australia, Karolinska Institutet
Enrollment target
~660 participants
Started
May 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gauti Jóhannesson
Umeå University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.